It is a leading threat to women's health, with lymph node metastasis a critical factor contributing to poor patient prognosis. Yet our understanding of the molecular mechanisms driving lymph node metastasis has been limited. A collaborative team of researchers has now constructed the comprehensive "cell-metabolism-immunity" landscape of the breast cancer lymph node metastatic microenvironment by integrating single-cell RNA sequencing and spatial transcriptomics. Researchers analyzed single-cell data from 78 paired primary breast cancer and lymph node metastasis samples, encompassing over 360,000 cells. By combining advanced genetic sequencing and spatial mapping, we have gained unprecedented insights into the dynamic changes and cellular communication patterns within the metastatic microenvironment." Cellular communication network analysis uncovered a sophisticated three-way interaction between lymphocytes, macrophages, and epithelial cells in the metastatic microenvironment. Specifically, M2-type macrophages secrete cytokines like CCL22 and CXCL12, inducing an immunosuppressive microenvironment while driving malignant transformation of EDCs. Spatial transcriptomics validated that these interactions form distinct spatial regions in lymph node tissues, overlapping with the tumor invasion front. "This systemic interaction between cancer cells, metabolism, and immunity is the core mechanism of lymph node metastasis and a potential therapeutic target," says co-lead investigator Tingming Liang, PhD, School of Life Science, Nanjing Normal University, Nanjing, China. The researchers identified four tyrosine kinase inhibitors targeting M2 macrophages, including pexidartinib hydrochloride and sunitinib malate. These drugs block immunosuppressive macrophage function by inhibiting key targets like CSF1R, thereby suppressing lymph node metastasis. "These drugs have demonstrated safety in treating other cancers, and our findings provide a theoretical basis for their application in breast cancer metastasis," notes Dr. Guo. "Future work will need to explore the metabolic vulnerabilities of EDCs and integrate clinical data to advance the development of innovative therapeutic strategies for patients." Deciphering the Cellular and Metabolic Landscape of Lymph Node Metastasis in Breast Cancer Using Single-Cell and Spatial Multi-Omics. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please check the box above to proceed. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

Wound healing is a multistep biological process involving inflammation, tissue formation, and remodeling. While inflammation is essential for clearing debris and recruiting repair cells, excessive or prolonged inflammatory responses can delay closure, increase fibrosis, and compromise tissue quality. However, previous studies have reported conflicting roles for NLRP3 in tissue repair, suggesting that its effects depend on timing and cellular context. Based on these challenges, it is necessary to investigate how NLRP3 regulates wound healing in a spatiotemporal and phase-specific manner. Researchers from the Chinese PLA General Hospital report that the NLRP3 inflammasome plays dual, time-dependent roles during acute wound healing, according to a study published (DOI: 10.1093/burnst/tkag002) in Burns & Trauma in January 2026. Using mouse and human wound models combined with multi-omics and single-cell analyses, the team demonstrates that NLRP3-driven inflammation is essential in early repair but becomes detrimental if sustained. Temporally modulating NLRP3 activity improved tissue regeneration, reduced scarring, and enhanced healing quality. By integrating transcriptomics, single-cell RNA sequencing, and functional experiments, the researchers mapped dynamic changes in NLRP3 activity throughout wound healing. During the early inflammatory phase, NLRP3 was highly expressed in macrophages and neutrophils, where it promoted chemokine production and immune cell recruitment. These signals facilitated macrophage and fibroblast migration to the wound site and supported pro-inflammatory macrophage polarization, accelerating early wound closure. Genetic deletion of Nlrp3, however, revealed a complex trade-off. Mechanistically, reduced inflammatory signaling allowed earlier activation of regenerative pathways such as Wnt and Notch. The study also uncovered an inflammasome-independent role for NLRP3 in fibroblasts. Together, these findings position NLRP3 as a molecular switch that links inflammation intensity to repair quality. "Inflammation is not simply beneficial or harmful—it has a timetable," said one of the senior investigators. The researchers noted that this timing-dependent mechanism helps explain why broad anti-inflammatory treatments often fail in wound care. Instead, controlling when and where inflammatory pathways are activated may be the key to improving healing outcomes. Rather than suppressing inflammation indiscriminately, future therapies could aim to fine-tune NLRP3 activity in a phase-specific manner—enhancing its function during early inflammation while limiting its effects during later repair. Such strategies may accelerate closure while reducing fibrosis and improving tissue regeneration. More broadly, this work provides a framework for understanding how temporally controlled immune responses shape tissue repair, with implications extending beyond skin wounds to other inflammation-driven regenerative processes. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

Advances in cancer treatment mean that more people than ever are surviving the disease. However, some of the most effective anticancer drugs-a class of medicines called anthracyclines-can cause serious damage to the heart. In some patients, this cardiac damage appears months or even years after treatment and has a major impact on quality of life. Now, a team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), led by Dr. Borja Ibáñez, provides new evidence that this can be achieved. The study, published in Basic Research in Cardiology, demonstrates in an experimental model that the heart can be protected during anthracycline treatment using a simple, non-pharmacological technique known as remote ischemic conditioning (RIC), without reducing chemotherapy's antitumor effectiveness. RIC consists of controlled, brief interruptions of blood flow to a limb, usually achieved by applying a pressure cuff similar to those used to measure blood pressure. The results show that animals receiving RIC maintained better cardiac function during treatment. Importantly, this cardioprotective effect was not associated with increased tumor growth or reduced antitumor efficacy of chemotherapy. The study's first author, Anabel Díaz Guerra, a CNIC predoctoral researcher funded by the Spanish Association Against Cancer (AECC), explains: "Showing that the heart can be protected without compromising cancer treatment is essential to developing safer therapies." The trial is evaluating whether RIC can protect the hearts of cancer patients treated with anthracyclines and reduce long-term cardiovascular complications. Senior CNIC investigator Dr. Laura Cádiz, co-supervisor of Díaz Guerra's thesis, notes that the findings "reinforce the idea that simple, non-invasive strategies can play a key role in cardiovascular protection for cancer patients and open new avenues to improve their quality of life during and after treatment." Through its Myocardial Homeostasis and Cardiac Damage Programme, Centro Nacional de Investigaciones Cardiovasculares (CNIC) investigates the cardiovascular toxicity of cancer treatments, particularly the damage caused by anthracyclines, with the aim of developing effective and safe therapies. Dr. Ibáñez's group leads major European projects such as the ERC Consolidator Grant "MATRIX" and the Horizon 2020–HEALTH project "RESILIENCE," in collaboration with Hospital Universitario Fundación Jiménez Díaz and CIBERCV, to reduce the incidence of heart failure among cancer survivors. Remote ischemic conditioning protects against anthracycline cardiotoxicity without impairing its antitumor activity. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please check the box above to proceed. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

The device detects inflammatory signals within minutes and collects specialized immune cells within hours without the need for blood draws or surgical biopsies. In the future, it could make it easier to track how people respond to vaccines, infections, and cancer therapies by complementing traditional blood tests and biopsies while being far easier on patients. Traditionally, studying some of the most important immune cells in the body requires a skin biopsy or blood draws. Because many of these cells live and respond in tissues like the skin, accessing them has meant invasive procedures. This is especially important in sensitive or visible areas like the face or neck, where people often don't want biopsies because of scarring, as well as for older adults, frail patients, and very young children or infants." Sasan Jalili, biomedical engineer and immunologist at JAX Initially developed during Jalili's postdoctoral training at MIT, the platform was further refined, optimized, and advanced from mouse models toward clinical application at JAX through collaborations with the University of Massachusetts Chan Medical School (UMass Chan). Most tests for monitoring immune cells and inflammatory biomarkers rely on bloodwork, but many of the cells that recognize specific infections, vaccines, or autoimmune triggers circulate only sparsely in blood. The patch works by harnessing resident memory T cells, immune sentinels that live in skin and other "barrier" tissues and rapidly respond to previously encountered foreign threats, or antigens. When these cells recognize a familiar antigen, such as a fragment of a virus or an allergen, they "sound the alarm," releasing signals to attract additional immune cells from the bloodstream, including the highly specialized T cells that recognize that same threat. By triggering this natural process, which concentrates key immune cells in the skin, the researchers deliberately assessed immune responses. "In this study, we used antigen-specific T cells as a proof of concept, but the patch also captures other immune cells and inflammatory biomarkers," said Jalili, who is also a joint faculty member at UConn School of Medicine. In a human test at UMass Chan, the patch also collected a rich mix of immune cells and signaling proteins, including resident memory T cells. "This study marks the first demonstration of live human immune cell sampling using a microneedle patch," Jalili said. "This opens the door to a new way of monitoring immune responses that's practical, painless, and clinically feasible." The patch absorbs immune cells and signaling proteins from the skin after resident memory T cells are briefly reactivated with a small amount of antigen. A seaweed-derived hydrogel also deemed safe by the FDA coats the needles and absorbs immune cells and molecules from skin interstitial fluid. But the early findings are particularly promising, said study co-author Darrell Irvine, an immunologist and bioengineer at Scripps Research, who began the work at MIT. "Not only did we run extensive preclinical experiments, we were able to carry out an initial test in humans," Irvine said. "That's exciting because it almost never happens with brand-new technologies. Moving new technologies from the lab to testing on patients often takes years." The patch may be especially useful for skin conditions, since immune cells that drive conditions such as allergic dermatitis, psoriasis, and vitiligo already live in the tissue. Jalili is already using it to study how age-related skin changes contribute to chronic inflammation and frailty in older adults as part of the Pepper Scholars Program in the UConn School of Medicine and UConn Center on Aging. Looking ahead, the patch could eventually support at-home monitoring, allowing patients with skin conditions to track unpredictable flare-ups. The technology could also be adapted for oral or nasal cavities, opening the door to monitoring mucosal immune responses. Even 15 to 30 minutes can be enough to detect inflammatory signals and get a sense of what's happening in the tissue," Jalili said. Leveraging tissue-resident memory T cells for non-invasive immune monitoring via microneedle skin patches. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

A new study shows how dysfunctional packaging of the neurotransmitter dopamine triggers toxic processes in neurons - and how this can be repaired with simple delivery of energy (ATP). Parkinson's gradually destroys dopamine-producing neurons in a specific area of the midbrain, causing tremors, stiffness, and movement problems. "Dopamine oxidizes to produce toxic substances and causes lasting damage to the neurons if it is not properly packaged in small bubbles, known as vesicles - but the cause of this dysfunctional packaging of dopamine was hitherto unclear," says Lena Burbulla, Professor of Metabolic Biochemistry in the Faculty of Medicine at LMU and member of the SyNergy Cluster of Excellence. The researchers converted induced pluripotent stem cells (iPSCs) from a Parkinson's patient with a defective DJ-1 gene and genetically modified iPSCs lacking the DJ-1 gene into neurons. Using high-precision protein analysis (proteomics), state-of-the-art imaging and sensitive dopamine sensors, the team of researchers revealed how dopamine is "packaged" incorrectly in the cells. The protein VMAT2, which is responsible for the secure packaging of dopamine into the vesicle, does not function properly in Parkinson's neurons: It does not take up enough dopamine - firstly because there is a lack of energy in the form of ATP (adenosine triphosphate), the universal energy carrier in cells, and secondly because the neuron does not produce enough VMAT2. As a result, dopamine ultimately oxidizes to form toxins. Another crucial factor here is that misfolded α-synuclein protein accumulates - probably a consequence of the oxidized dopamine, which can bind proteins and promote their accumulation. This discovery links an energy deficiency to the packaging of dopamine and neuron vulnerability - a new mechanism for Parkinson's." It shows that intact VMAT2 and secure packaging of dopamine are key factors for protecting midbrain neurons and preserving them could slow down the pathology. "iPSC-based disease modeling will enable future therapy tests to be conducted directly in patient cells and will accelerate translation from laboratory to clinic." VMAT2 dysfunction impairs vesicular dopamine uptake, driving its oxidation and α-synuclein pathology in DJ-1–linked Parkinson's neurons. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please check the box above to proceed. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

Star Quinn moved to Kingsport, Tennessee, in 2023, the same year the state began covering dental costs for about 600,000 low-income adults enrolled in Medicaid. But when Quinn chipped a tooth and it became infected, she could not find a dentist near her home who would accept her government health coverage and was taking new patients. She went to an emergency room, receiving painkillers and antibiotics, but she remained in agonizing pain weeks later and paid a dentist $200 to extract the tooth. The federal government has long required states to offer dental coverage for children enrolled in Medicaid, the joint state-federal health program for people who are low-income or disabled. But under congressional Republicans' One Big Beautiful Bill Act, which President Donald Trump signed into law last year, the federal government is expected to reduce Medicaid spending by more than $900 billion over the next decade. State Medicaid programs typically expand or reduce benefits depending on their finances, and such massive federal cuts could force some to shrink or eliminate what they offer, including dental benefits. "We will lose all the gains we have made," said Shillpa Naavaal, a dental policy researcher at Virginia Commonwealth University in Richmond. Tennessee's Medicaid program, for instance, spent nearly $64 million on its dental coverage in 2024 and saw a 20% decrease in dental-related ER visits, said Amy Lawrence, the program's spokesperson. As of last year, 38 states and the District of Columbia offered enhanced dental benefits for adult Medicaid beneficiaries, according to the American Dental Association. Most of the others offer limited or emergency-only care. Alabama is the only state that offers no dental coverage for adult beneficiaries. Since 2021, 18 states have enhanced their coverage to include checkups, X-rays, fillings, crowns, and dentures, while loosening annual dollar caps for benefits. Use of dental benefits in states with the enhanced benefits is greater than in states with only limited or emergency coverage, though still low overall, according to an ADA report with the latest data as of December. To review more recent progress, KFF Health News asked one-third of the states that have expanded their benefits in the past five years for their most recent data on the percentage of adults on Medicaid who visit a dentist at least once a year: In comparison, about 50% to 60% of adults with private dental coverage see a dentist at least once a year, according to the ADA. Reimbursement rates have not kept up with costs, deterring dentists from accepting Medicaid, said Marko Vujicic, chief economist and vice president at the ADA Health Policy Institute. Because of a lack of dentists who take Medicaid in southwestern Virginia, the Appalachian Highlands Community Dental Center in Abingdon sees patients who travel more than two hours for care — and must turn many away, said Elaine Smith, its executive director. The center's seven residents treated about 5,000 patients last year, most of them on Medicaid. "It's sad because they have the means now to see a dentist, but they still don't have a dental home," Smith said. The inability to see a dentist has consequences broader than tooth pain. Robin Mullins, 49, who has been off and on Medicaid since 2013, said a lack of regular dental visits contributed to her losing her bottom teeth. Unable to find a dentist near her home in rural Clintwood, Virginia, she drives almost 90 minutes to Smith's clinic — that is, when she can afford to get time away from driving for DoorDash or find help watching her daughter, who has special needs. "It's absolutely horrible, as you can't chew your food properly." In New Hampshire, though, the challenges have more to do with low demand than a low supply of dentists, said Tom Raffio, chief executive of Northeast Delta Dental, which manages the state's Medicaid dental program. The company has added new dentists to its list of participating providers, along with two mobile dental units that traverse the state, he said. Raffio said Northeast Delta Dental also has publicized the state benefits using radio advertising and social media, among other efforts. Brooks Woodward, dental director at Baltimore-based Chase Brexton Health Care, called Maryland's rate of roughly 1 in 5 adults on Medicaid seeing a dentist in 2024 "pretty good" considering the benefits had been enhanced only since 2023. "They've always just not gone to the dentist, and that's just the way they had it in their life," he said. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

Disclosure: Julia Szendrödi, MD, PhD, has disclosed no relevant financial relationships. Disclosure: Julia Szendrödi, MD, PhD, has disclosed no relevant financial relationships. With incretin-based medications such as semaglutide and tirzepatide, obesity treatment has fundamentally changed in recent years. Intervention trials have shown weight reductions of up to 20%, and for the first time, positive endpoint data on cardiovascular events and mortality are available. However, in routine clinical practice, the initial enthusiasm has moderated. How can new pharmacologic options be meaningfully integrated into a comprehensive obesity treatment strategy? Medscape's German edition spoke with Julia Szendrödi, MD, PhD, medical director of the Clinic for Endocrinology, Diabetology, Metabolic Diseases, and Clinical Chemistry at Heidelberg University Hospital in Heidelberg, Germany. Professor Szendrödi, after several years of experience, what do you do differently today when using incretin-based medications compared with the beginning? The results of the intervention trials were impressive, and of course we wanted to achieve similar effects for our patients. Today, I consistently start with the lowest dose and no longer automatically escalate according to a fixed schedule. After several weeks, I have a structured discussion with patients about tolerability, appetite suppression, and quality of life during treatment. In some patients, quality of life is so significantly impaired that the satisfaction from weight loss does not compensate for it. In such cases, it may make sense to remain at a lower dose. Nutrient deficiencies and muscle loss have also been discussed. Nutrient deficiencies are more common in people with obesity than one might expect, and they tend to increase under incretin-based therapy. Therefore, we always accompany pharmacologic therapy with nutritional management. Some degree of muscle loss cannot be completely avoided during weight reduction because weight loss does not consist solely of fat mass. There are already promising research approaches addressing this issue, such as combining incretin-based medications with agents aimed at preserving muscle mass. For now, however, it is essential that patients pay close attention to protein intake. Ideally, they should receive dietary counseling and incorporate structured physical activity into their daily routine, including strength training whenever possible. What should be done once the desired weight loss has been achieved? Just because a target value has been reached does not automatically mean therapy should be stopped. One option is to continue treatment at a reduced dose. If medication is discontinued, it is crucial that weight loss has been well supported and that lifestyle measures are consistently maintained — not only in terms of diet but also physical activity and daily structure. With the availability of new weight-loss medications, does bariatric surgery still have a place in obesity treatment? Obesity treatment continues to rest on three pillars: lifestyle intervention, pharmacologic therapy, and bariatric surgery. In cases of severe obesity, significant comorbidities, or insufficient response to medication, surgery remains the most effective option. The advantage today is that medications can complement surgery — preoperatively to reduce risk or postoperatively in cases of weight plateau or regain. You have mentioned diet and exercise several times. Diet and physical activity remain the foundation of treatment. However, in cases of severe obesity, they are usually insufficient on their own to achieve substantial and sustained weight reduction. In clinical trials, lifestyle intervention can be effective — but under very intensive supervision, which often involves costs comparable to medication or surgery. Nevertheless, lifestyle therapy has not lost its importance. On the contrary, it is crucial for preserving muscle mass, maintaining metabolic health, sustaining physical performance, and stabilizing long-term weight loss — regardless of how that weight loss was achieved. Today, the focus is no longer on short-term weight loss but on sustainable outcomes: long-term weight reduction, remission of prediabetes or diabetes, and durable reduction of comorbidities and mortality. However, outdated legislation stands in contrast to this shift. In Germany, the so-called “lifestyle clause” in health policy still prevents routine reimbursement of obesity medications, based on the outdated notion that obesity is primarily a matter of willpower and discipline. We now understand that the causes are more complex? We now know that satiety and energy homeostasis are regulated through neurohormonal mechanisms and that genetic predisposition plays a major role — as do metabolic factors such as hyperinsulinemia. Treatment with incretin-based medications relieves a tremendous burden for many patients. They report that for the first time, they are no longer constantly thinking about food because appetite is significantly reduced.

By harnessing everyday clinical assessments, researchers demonstrate that personalized 12-month forecasts of cognitive and functional change in dementia can be achieved without expensive imaging or invasive testing. Finally, a decision support tool was designed to deploy both predictive models in clinical settings (f). MMSE: Mini-mental state exam, ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale, BADL: Bristol Activities of Daily Living In a recent study published in the journal Communications Medicine, a group of researchers developed and validated scalable machine learning models that predict 12-month Mini-Mental State Examination (MMSE) and Bristol Activities of Daily Living (BADL) scores, enabling individualized forecasts of cognitive and functional trajectories, in Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) using routinely collected clinical data. Nearly 60 million people worldwide are living with dementia, and that number is expected to double by 2050. Families often ask how quickly can AD or MCI progress, as every person faces the consequences differently. Some people's health declines fast, while others stay stable for years. Current guidelines based on average patient data often fail to capture this variability. Accurate, accessible tools that personalize predictions could transform care planning, but more research is needed to develop scalable and clinically viable prognostic models. Clinical, demographic, and medical history data were obtained from the Minder Health Management Study in the United Kingdom, an ongoing longitudinal study of people living with dementia. Researchers included only AD or MCI patients with at least 1 year of follow-up data. Each individual non-overlapping 12-month period was considered an independent clinical trajectory, an analytical assumption that treats repeated periods from the same individual as statistically independent. Baseline features included age, sex, comorbidities derived from Electronic Health Records using International Statistical Classification of Diseases and Related Health Problems, 10th Revision categories, and detailed sub-item scores from three assessments: the Mini-Mental State Examination (MMSE), the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and the Bristol Activities of Daily Living (BADL). Two ElasticNet regression models were fitted to estimate 12-month MMSE and BADL scores. External validation was conducted only for the MMSE model, as comparable BADL data were not available in the ADNI cohort. The best-performing cognitive model, based on ElasticNet regression, predicted 12-month MMSE scores with a MAE of 1.84 points (95% Cl: 1.64-2.04) and an R² of 0.74. External validation on the Alzheimer's Disease Neuroimaging Initiative dataset yielded a comparable MAE of 2.19, despite demographic and baseline severity differences between the cohorts. Importantly, prediction error remained below the standard deviation of decline in both datasets, a comparison the authors interpret as suggesting clinically meaningful accuracy, although no formal clinical decision thresholds were predefined. The functional model predicted 12-month BADL scores with a MAE of 3.88 points (95% Cl: 3.46-4.30) and an R² of 0.77, demonstrating similarly strong performance. Baseline total scores alone did not fully explain progression rates. Instead, specific cognitive and functional subdomains were highly predictive. For cognitive decline, lower baseline performance in ideational praxis, word recall, spoken language, word recognition, and MMSE orientation and visuospatial items strongly predicted steeper MMSE decline. For functional decline, independence in food and drink preparation, managing finances, dressing, shopping, and engagement in hobbies were among the strongest predictors. Individuals already struggling in these domains were more likely to experience greater loss of independence over 12 months. Age was also significantly associated with a faster rate of functional decline. Interestingly, comorbidities were not strong predictors in either model. Models performed similarly, or slightly better, without comorbidity features, particularly for functional prediction, suggesting that detailed cognitive and functional baseline patterns carried more prognostic weight than broad disease categories. These analyses indicate that the predictions are personalized for each patient based on their specific cognitive and functional profile. The findings indicate that it is possible to create reliable individualized predictions of dementia progression based solely on frequently collected clinical assessments without the need for neuroimaging or cerebrospinal fluid biomarkers. The team also implemented a clinician-facing decision-support tool, termed Theia, which generates predicted 12-month scores alongside SHAP-based explanations to enhance interpretability in practice. However, the relatively modest sample size used for model development and the use of research-cohort data for external validation suggest that broader multi-center validation in routine-care populations will be important before widespread deployment. The models demonstrated strong internal validity and external validation for cognitive prediction, with clinically meaningful error margins. Importantly, specific cognitive and daily living subdomains were more predictive than total scores alone. When applied in a clinical context, they can assist with individualized care planning, improve resource utilization, and provide clearer expectations to patients and their families, introducing precision forecasting into daily dementia care. His academic journey has allowed him to delve deeper into understanding the intricate world of microorganisms. He has worked on diverse projects in microbiology, biopolymers, and drug delivery. His contributions to these areas have provided him with a comprehensive understanding of the subject matter and the ability to tackle complex research challenges. Please use one of the following formats to cite this article in your essay, paper or report: Machine learning predicts who will decline faster in Alzheimer's disease using routine clinic data. "Machine learning predicts who will decline faster in Alzheimer's disease using routine clinic data". "Machine learning predicts who will decline faster in Alzheimer's disease using routine clinic data". Machine learning predicts who will decline faster in Alzheimer's disease using routine clinic data. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

A sweeping national analysis suggests that counties nearer to nuclear power plants experience higher cancer mortality, raising urgent questions about long-term environmental exposure, aging populations, and the limits of proximity-based risk assessment. Study: National analysis of cancer mortality and proximity to nuclear power plants in the United States. A recent study published in the journal Nature Communications reports higher cancer mortality rates in the United States (US) counties within 200 km of operational nuclear energy plants compared with more distant counties, with the greatest burden observed among older adults. Estimated attributable cancer deaths were highest among adults aged between 65 and 74 years, with an estimated 13,976 deaths in females and 20,912 in males. Although the findings do not establish causation, they underscore the importance of examining possible exposure routes, long-term health impacts, and cancer outcomes with broader public health implications. Nuclear energy plants remain a primary source of electricity worldwide and are increasingly being viewed as a low-carbon energy option. However, routine operations can release small amounts of radioactive pollutants into the air, water, and soil, creating potential pathways for human exposure through inhalation, ingestion, or direct contact. Chronic low-level exposure to ionizing radiation, a well-established carcinogen, has raised longstanding public health concerns for communities living nearby. Importantly, the study did not measure individual radiation exposure or dosimetry; instead, it used geographic proximity as a proxy for potential exposure, assuming equal contribution from all operational plants within 200 km regardless of plant size or emissions. Prior studies have explored links between residential proximity to nuclear facilities and cancer risk; however, results are inconsistent. Moreover, most US investigations were geographically limited and relied on simplified exposure metrics, underscoring the need for more comprehensive, methodologically robust analyses. In the present study, researchers examined long-term spatial patterns of cancer mortality based on county-level proximity to nuclear facilities between 2000 and 2018. They investigated whether living closer to nuclear energy facilities could increase cancer mortality risk, accounting for demographic, socioeconomic, environmental, healthcare, and behavioral factors. They calculated proximity by summing the inverse-distance weights from all operational nuclear plants within 200 km of each county center. The analysis included facilities located in Canada but within 200 km of a US county center. They determined relative risks (RRs) using generalized estimating equation (GEE) Poisson regression models. Study covariates included age, body mass index, race, education, income, smoking prevalence, population density, relative humidity, temperature, proximity to the nearest hospital, and physician visits among those aged 65 years and older. Further, the team performed a sensitivity analysis by restricting to counties within 100 km of nuclear facilities, evaluated in 10 km increments. They also examined multiple exposure windows ranging from 2 to 20 years. Lastly, the team assessed mortality risks associated with proximity to coal-fired power plants for comparison, providing context for the observed associations. The analysis revealed significantly higher cancer mortality rates in US counties located closer to nuclear energy plants than in those farther away. Overall, the annual estimated attributable cancer mortality among individuals aged 65 years and older living near nuclear facilities averaged 4,266 deaths between 2000 and 2018. A clear distance pattern emerged, with cancer mortality risk highest at shorter distances from nuclear plants and gradually declining with increasing distance. Geographically, counties in the Northeast, Midwest, and parts of the Southeast were generally closer to nuclear facilities, whereas those in the Great Plains and Western regions tended to be farther away due to a sparser distribution of nuclear plants. For a broader context, prior research has estimated that annual all-cause mortality linked to coal-fired power plant emissions averaged 20,909 deaths between 1999 and 2020. Although not directly comparable due to differences in outcomes and study design, the current findings represent approximately 20% of that figure, underscoring the cancer burden potentially associated with energy-related environmental exposures. Overall, the findings suggest that US counties in proximity to nuclear energy plants experience higher cancer mortality rates than those situated farther away, highlighting the need to more closely examine the long-term public health implications of nuclear energy infrastructure. However, the ecological design, based on county-level data from the CDC, does not account for individual-level exposure or risk factors, nor does it capture lifetime residential history or migration patterns, limiting causal interpretation. Future research should incorporate direct radiation measurements, including dosimetry, and evaluate vulnerable populations such as children. Studies exploring site-specific cancers, varying latency periods, and radiation sensitivities are also warranted. In addition, expanding investigations to include cardiovascular, neurological, and other health outcomes could provide a more comprehensive understanding of the broader health impacts of living near nuclear facilities. Her academic background is in Oral Medicine and Radiology. Please use one of the following formats to cite this article in your essay, paper or report: Living near nuclear power plants is associated with higher cancer mortality, national US study reports. "Living near nuclear power plants is associated with higher cancer mortality, national US study reports". "Living near nuclear power plants is associated with higher cancer mortality, national US study reports". Living near nuclear power plants is associated with higher cancer mortality, national US study reports. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.

A large genetic analysis suggests that one amino acid linked to protein metabolism could influence how long we live, with potential sex-specific effects that challenge assumptions about diet and longevity. Dietary protein restriction has been reported to increase lifespan. Amino acids that respond to protein restriction may influence lifespan. For instance, tyrosine has been demonstrated to regulate physiological responses to a low-protein diet in an animal study. Further, restricting tyrosine intake modulates amino acid-sensing pathways, reduces endogenous tyrosine, and extends lifespan in experimental models. Further, elevated levels of phenylalanine, which is the precursor of tyrosine, are associated with telomere loss, type 2 diabetes, and inflammatory diseases. Evidence shows that phenylalanine is oxidized to meta-tyrosine, a toxic metabolite reported to reduce lifespan in Caenorhabditis elegans. However, the role of these amino acids has been rarely studied in humans. First, they used Cox regression to evaluate associations between baseline plasma levels of tyrosine and phenylalanine and all-cause mortality in the United Kingdom Biobank (UKB) cohort; the analysis was adjusted for sex, age, smoking, alcohol intake, ethnicity, body mass index, physical activity, education, and the Townsend Deprivation Index. In addition, associations of tyrosine and phenylalanine levels with cancer and cardiovascular disease (CVD) mortality were assessed. Next, the researchers conducted combined and sex-specific genome-wide association studies (GWASs) of tyrosine and phenylalanine in the UKB. Genetic instruments for circulating tyrosine and phenylalanine were derived from the GWASs. Specifically, SNPs linked to circulating tyrosine or phenylalanine at genome-wide significance were selected. The team used genome-wide significant SNPs associated with tyrosine and phenylalanine in the UKB in a two-sample Mendelian randomization (MR) analysis, and applied them to a GWAS of parental attained age (a proxy for lifespan) in a European ancestry population to estimate the effect on lifespan. Finally, multivariable MR analyses were performed to assess the independent effects of tyrosine and phenylalanine. About 272,475 individuals from the UKB cohort with data on amino acid levels, confounders, and death status were included. Plasma phenylalanine was associated with higher all-cause mortality overall, and in both sexes. Similarly, plasma tyrosine was associated with an elevated risk of mortality overall and in males alone. These associations persisted in a sensitivity analysis that excluded deaths from accidents. A higher tyrosine-to-phenylalanine ratio was associated with a lower risk of all-cause mortality overall and in females. In disease-specific mortality analysis, plasma phenylalanine was associated with cancer and CVD mortality, whereas tyrosine showed no associations. Restricted cubic spline analyses suggested potential non-linearity in the associations, with turning points near the population mean concentrations, indicating that associations were more pronounced at higher circulating levels. Following exclusion of correlated genetic variants, 74 and 21 SNPs were used as genetic instruments for tyrosine and phenylalanine in the combined analysis. SNPs associated with these amino acids were located in genes crucial for amino acid regulation, metabolism, and transport. The essential genes for phenylalanine were phenylalanine hydroxylase (PAH), solute carrier family 17 member 1 (SLC17A1), SLC43A1, SLC38A4, carbamoyl phosphate synthase 1 (CPS1), glutathione S-transferase mu 1 (GSTM1), and glutathione S-transferase alpha 2 (GSTA2). For tyrosine, these were PAH, GSTM1, 4-hydroxyphenylpyruvate dioxygenase (HPD), and CPS1. Genetically predicted elevated phenylalanine levels were associated with a longer lifespan in males only. In multivariable MR, phenylalanine was no longer associated with lifespan in either sex after controlling for tyrosine. In contrast, tyrosine was associated with shorter lifespan, particularly in males, after controlling for phenylalanine, with weaker and less consistent evidence in females, depending on the analytic method used. In sum, genetically predicted higher tyrosine levels were associated with a shorter lifespan, and the association was sustained in males independent of phenylalanine; in contrast, phenylalanine was not independently associated with lifespan. These results underscore the potential role of tyrosine in human longevity and warrant further investigation. Importantly, Mendelian randomization estimates reflect the lifelong effect of endogenous circulating levels rather than short-term dietary supplementation. The authors also noted limited statistical power to detect sex differences and acknowledged that partial sample overlap between the exposure and outcome datasets could introduce bias, although sensitivity analyses showed consistent effect directions. Tarun is a writer based in Hyderabad, India. He has a Master's degree in Biotechnology from the University of Hyderabad and is enthusiastic about scientific research. Please use one of the following formats to cite this article in your essay, paper or report: Higher tyrosine levels linked to shorter lifespan in major UK Biobank analysis. "Higher tyrosine levels linked to shorter lifespan in major UK Biobank analysis". "Higher tyrosine levels linked to shorter lifespan in major UK Biobank analysis". Higher tyrosine levels linked to shorter lifespan in major UK Biobank analysis. Discover how Bruker is helping drive innovation in cosmetic science through advanced AFM techniques. Discover how Thermo Fisher is shaping the future of plant-based foods through texture innovation and cultural relevance. Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content. A few things you need to know before we start. Please check the box above to proceed. While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information.